Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin

Circulation Research

Volumn 96, Issue 11, 2005, Pages 1193-1199

  Goldman, Jeremy ^a   Le, Thomas X ^a   Skobe, Mihaela ^b   Swartz, Melody A ^a,c  

^a Northwestern University   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c EPFL   (Switzerland)

Author keywords

Chemotaxis; Lymphatic endothelial cell; Mouse; VEGFR 3

Indexed keywords

VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPERPLASIA; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; TISSUE REGENERATION;

ANIMALS; CELL MOVEMENT; CHEMOTAXIS; ENDOTHELIAL CELLS; HUMANS; HYPERPLASIA; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; REGENERATION; SKIN PHYSIOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 20444463986     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000168918.27576.78     Document Type: Article

References (21)

1. Alitalo K, Carnieliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002;1:219-227.
2. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Ravala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276:1423-1425.
3. Veikkola T, Alitalo K. Dual role of Ang2 in postnatal angiogenesis and lymphangiogenesis.[comment]. Dev Cell. 2002;3:302-304.
4. Saaristo A, Veikkola T, Enholm B, Hytonen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Yla-Herttuala S, Alitalo K. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J. 2002;16: 1041-1049.
5. Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Yla-Herttuala S, Alitalo K. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.[erratum appears in Circ Res 2001 Jul 6;89:E15]. Circ Res. 2001;88:623-629.
6. Szuba A, Skobe M, Karkkainen MJ, Shin, WS, Beynet DP, Rockson NB, Dakhi N, Spilman S, Goris ML, Strauss UW, Quertermous T, Alitalo K, Rockson SG. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;16:1985-1987.
7. Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, Wecker A, Kirchmair R, Hu CS, Kearney M, Ashare A, Jackson DG, Kubo H, Isner JM, Losordo DW. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest. 2003;111:717-725.
8. Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 2004;64:4400-4404.
9. Boardman KC, Swartz MA. Interstitial flow as a guide for lymphangiogenesis. Circ Res. 2003;92:801-808.
10. Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC, Swartz MA. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 2005;97:14-21.
11. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001;20:4762-4773.
12. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med. 2001;7:192-198.
13. Swartz MA, Berk DA, Jain RK. Transport in lymphatic capillaries: I. Macroscopic measurment using residence time distribution analysis. Am J Physiol. 1996;270:H324-H329.
14. Banerji S, Ni J, Wang S, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
15. Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS, Skobe M. Molecular characterization of lymphatic endothelial cells. [erratum appears in Proc Natl Acad Sci USA. 2003 Apr 15:100:4970]. Proc Natl Acad Sci U S A. 2002;99:16069-16074.
16. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol. 2003;160:267-277.
17. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol. 2004;16:14-23.
18. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol. 2001;17:463-516.
19. Saaristo A, Veikkola T, Tammela T, Enholm B, Karkkainen MJ, Pajusola K, Bueler H, Yla-Herttuala S, Alitalo K. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med. 2002;196:719-730.
20. Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J, Shapiro SD, Kolattukudy PE. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res. 2000;87:378-384.
21. Skobe M, Hamberg LM, Hawighorst T, Shapiro SD, Kolattukudy PE, Schirner M, Wolf GL, Alitalo K, Detmar M. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol. 2001; 159:893-903.